Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

NCT03919071 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03919071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03919071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 20, 2020
Completion date
September 30, 2027
Enrollment
58 (estimated)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic astrocytoma, not otherwise specified, anaplastic ganglioglioma, anaplastic pleomorphic xanthoastrocytoma, glioblastoma, malignant glioma, who grade 3 glioma, who grade 4 glioma